Valuing Biotechnology Patents and Companies




About the Course:

This session provides profound insights into deciphering the Food and Drug Administration’s biotech approval process. Robert LeBoyer — a leading biotech analyst with nearly 25 years of experience — discusses a variety of technology, clinical, regulatory, sales and marketing, and capital risks associated with evaluating biotech companies.

This course includes commentary on a variety of valuation issues that arise in connection with monoclonal antibodies, cell receptors, and intracellular signaling. A review of developments in cutting-edge technologies such as genomics, gene therapy, and RNAi is provided. Drivers of biotech products targeted towards cancer, infectious diseases, cardiovascular diseases, and orphan drugs is a particularly practical segment of this program.

This course illustrates financial analysis by providing a Product Pipeline Table, a Pipeline Valuation, a Biotech Company Revenue Projection, and a Comparable Company Table.

Course Length: Approx. 1.5 hours

IIPLA IP Conference and Exhibition in 2022 Banner

IIPLA 2021 Hybrid Conference Banner


There are no reviews yet.

Be the first to review “Valuing Biotechnology Patents and Companies”
Thanks for submitting your comment!